Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.55 |
| ▸ | GRM5 | P41594 | 5/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | PRKACB | P22694 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527041 | 1.00 | PARP11 (0.55) | PARP11PARP10GRM5GABRG2GABRB3 | |
| SCHEMBL379341 | 0.83 | GRM5 (0.67) | PARP11PARP10GRM5PARP1PDPK1 | |
| SCHEMBL8323443 | 0.83 | GRM5 (0.67) | PARP11PARP10GRM5PARP1PDPK1 | |
| SCHEMBL19574541 | 0.83 | PARP11 (0.55) | PARP11PARP10GRM5GABRG2GABRB3 | |
| SCHEMBL8542496 | 0.82 | PARP11 (0.51) | PARP11PARP10GRM5GABRG2GABRB3 | |
| SCHEMBL1036450 | 0.80 | KCNA5 (0.53) | PARP11PARP10GRM5GABRG2GABRB3 | |
| SCHEMBL9740545 | 0.79 | MAOB (0.57) | — | |
| SCHEMBL25597402 | 0.79 | PARP11 (0.50) | PARP11PARP10GRM5GABRG2GABRB3 | |
| Hydrochloric Acid SCHEMBL12502617 | 0.79 | PARP11 (0.50) | PARP11PARP10GRM5GABRG2GABRB3 | |
| SCHEMBL1239440 | 0.79 | PARP11 (0.50) | PARP11PARP10GRM5GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810041-B | Halogenated allylamine SSAO/VAP-1 inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-03-11 | — | — | US | disclosed |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3715341-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-09-30 | — | — | EP | disclosed |
| EP-3715341-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019101086-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | VAPB, VAPA, ADRA1D | PARP11 402/4885PARP10 984/4885GRM5 4666/4885 |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | VAPB, VAPA, ADRA1D | PARP11 402/4885PARP10 984/4885GRM5 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.